Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNORARE5 domvanalimab + zimberelimab platform study in advanced rare cancers
2024-517254-99-00Phase 2Suspended
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of domvanalimab and zimberelimab in peritoneal mesothelioma, trophoblastic tumour, thymoma and 4 more (5 cohorts), sponsored by Hospices Civils de Lyon. Primary endpoints: Progression-free survival rate at 24 weeks, Successful hCG normalization rate at 24 weeks and 1 more. Started Sep 2025; status: suspended.
02
Drugs
domvanalimabzimberelimab
03
Conditions
peritoneal mesotheliomatrophoblastic tumourthymomathymic carcinoma (TC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on 2024-517254-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517254-99-00.